Top Markets
Coin of the day
Galera Therapeutics, Inc. Galera Therapeutics, Inc.

Galera Therapeutics, Inc.

GRTX
Rank in Stocks #33959
Galera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical... Galera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation and commercialization of therapies aimed at revolutionizing cancer radiotherapy. Its lead investigational drug, avasopasem manganese (GC4419), functions as a small molecule superoxide dismutase mimetic. This compound has successfully completed a Phase III clinical trial targeting severe oral mucositis induced by radiation therapy in head and neck cancer (HNC) patients. Furthermore, GC4419 is currently undergoing Phase IIa clinical trials for radiotherapy-induced esophagitis in lung cancer patients, as well as for HNC patients undergoing standard-of-care radiation treatment. The company is also progressing with GC4711, another superoxide dismutase mimetic candidate, which is in a Phase I/II clinical trial. This trial evaluates its combination with stereotactic body radiation therapy (SBRT) for individuals diagnosed with non-small cell lung cancer and locally advanced pancreatic cancer. Galera Therapeutics was founded in 2012 and maintains its headquarters in Malvern, Pennsylvania.
Share Price
$17.15
Last synced: 2026-08-03
Market Cap
$6.51M
Change (1 day)
9.80%
Change (1 year)
289.77%
Country
US
Trade Galera Therapeutics, Inc. (GRTX)

Category

Number of shares outstanding for Galera Therapeutics, Inc. (GRTX)
Number of shares outstanding as of March 2026: 98.62M
According to Galera Therapeutics, Inc. latest financial reports and stock price the company's current number of shares outstanding is 98.62M. At the end of December 2023 the company had 44.55M shares outstanding. The number of outstanding shares is usually impacted by stock plits and shares buy back.
Shares outstanding history for Galera Therapeutics, Inc. (GRTX) from 2017 to 2026
Shares Outstanding at the end of each year
Year Shares Outstanding Change
2026 (TTM) 98.62M 80.52%
2024 54.63M 22.64%
2023 44.55M 64.47%
2022 27.09M 5.03%
2021 25.79M 3.70%
2020 24.87M 0.24%
2019 24.81M 28.15%
2018 19.36M -98.73%
2017 1.52B 0.00%
Shares Outstanding for similar companies or competitors
Company Shares Outstanding Difference Country
253.90M 157.45%
US
62.19M -36.95%
NL
- -
CH
- -
KR
0.00 -100.00%
BE